5-ASA for Ulcerative Colitis

Samuel Meyers, Henry D. Janowitz, Kenneth W. Schroeder, William J. Tremaine, Duane M. Ilstrup, Bernard F. Morrey

Research output: Contribution to journalLetterpeer-review


To the Editor: The therapeutic results reported in the paper entitled “Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis” (Dec. 24 issue)1 were very encouraging, in view of our previously reported data with olsalazine sodium.2 However, we were surprised that the patients in the placebo group were denied available standard therapy, in the form of sulfasalazine. The authors themselves stated that sulfasalazine is effective to “induce remission of mildly to moderately active disease.” In our study, the placebo group was limited to patients who were intolerant of or allergic to sulfasalazine.2 We considered entry into the.

Original languageEnglish (US)
Pages (from-to)1620-1621
Number of pages2
JournalNew England Journal of Medicine
Issue number24
StatePublished - Jun 16 1988
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of '5-ASA for Ulcerative Colitis'. Together they form a unique fingerprint.

Cite this